QNCXNMSHealthcare·Biotechnology#534 in industry

Quince Therapeutics, Inc.

Reports in 17d· 2026-05-13

-96.2% · 90d

$1.27

-0.10 (-6.99%)

News

(1)

April 2026

Apr 10, 20262 weeks ago10-KHealthcare

Quince Therapeutics (QNCX) Seeks Reverse Merger After Trial Failure

QNCXQuince Therapeutics, Inc.

# 🧾 What This Document Is This is Quince Therapeutics' 10-K, which is its **annual report** filed with the SEC. Think of it as the company's full-year report card for investors, covering everything from finances to risks. This one tells a story of a company in serious trouble after a major clinical

Read summaryView on SEC EDGAR

Key Data

Market Cap$20.6M

Open$1.32

Prev Close$1.36

Day Range$1.25 – $1.34

52W Range$0.80 – $45.50

Volume836,998

P/E (TTM)—

EPS$-16.80

Dividend Yield—

Beta1.33

Price Target$0.00

Next Earnings2026-05-13(17d)

Analyst Ratings

Hold3 analysts

Buy 0Hold 3Sell 0

About

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Healthcare · Biotechnology

38 employees

www.quincetx.com